PFSA · Profusa, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“As of June 30, 2026, there continue to be factors which raise substantial doubt about the Company's ability to continue as a going concern within one year from the date the condensed consolidated financial statements are issued.”View the 10-Q filed Aug 19, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Aug 17, 2026; bars on opposite sides are not compared.
The closing range begins at the captured split on Aug 17, 2026.
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PFSA
this stock
Profusa, Inc.
|
$2.07M | — | — | — | 1.8% |
|
ABT
Abbott Laboratories
|
$195.90B | -10.2% | +5.7% | 31.5 | 1.2% |
|
SYK
Stryker Corp
|
$127.12B | -5.9% | +11.2% | 34.3 | 1.8% |
|
MDT
Medtronic plc
|
$115.17B | -5.0% | +8.4% | 24.1 | 1.1% |
|
BSX
Boston Scientific Corp
|
$68.44B | -50.9% | +12.5% | 19.1 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Aug 17, 2026; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PFSA | -46.3% | — | — | — | — |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | -46.8% | — | — | — | — |